Experience with carboplatin and etoposide maintenance chemotherapy in patients with extensive stage small cell lung cancer [0.03%]
顺铂和依托泊苷维持化疗治疗广泛期小细胞肺癌患者的疗效分析
Amaan Siddiqi,Huzefa Bahrain,Michael Auerbach
Amaan Siddiqi
Purpose: To determine whether maintenance therapy with carboplatin and etoposide improves progression-free and overall survival in patients with extensive stage small cell lung cancer, compared to the standard four to six...
Matthew J Eadens,Steven I Robinson,Katharine Ar Price
Matthew J Eadens
Maintenance therapy for advanced nonsmall cell lung cancer has shown some clinical benefit for patients by improving progression-free survival and, to a lesser extent, overall survival. Two main strategies exist for maintenance therapy, ie,...
Pier Luigi Filosso,Alberto Sandri,Alberto Oliaro et al.
Pier Luigi Filosso et al.
Lung cancer (LC) has become the leading cancer-related cause of death in the US and in developed European countries in the last decade. Its incidence is still growing in females and in smokers. Surgery remains the treatment of choice whenev...
Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer [0.03%]
吉非替尼治疗转移性非小细胞肺癌的疗效和安全性评估
Serena Ricciardi,Silverio Tomao,Filippo de Marinis
Serena Ricciardi
Lung cancer is the leading cause of cancer deaths worldwide. Targeting the epidermal growth factor receptor (EGFR) has played a central role in advancing non-small-cell lung cancer (NSCLC) research, treatment, and patient outcome over the l...
Ganesan Kathiresan,Reynold F Clement,Meera T Sankaranarayanan
Ganesan Kathiresan
Dyspnea is a common and distressing symptom experienced by 19%-51% of patients with advanced cancer. Higher incidences are reported in patients approaching end of life. While the prevalence of dyspnea has been reported to be as frequent as ...
Azacitidine and decitabine have different mechanisms of action in non-small cell lung cancer cell lines [0.03%]
阿扎胞苷和地西他滨在非小细胞肺癌细胞系中的作用机制不同
Aaron N Nguyen,Paul W Hollenbach,Normand Richard et al.
Aaron N Nguyen et al.
Azacitidine (AZA) and decitabine (DAC) are cytidine azanucleoside analogs with clinical activity in myelodysplastic syndromes (MDS) and potential activity in solid tumors. To better understand the mechanism of action of these drugs, we exam...
Genome-wide gene expression analysis of chemoresistant pulmonary carcinoid cells [0.03%]
肺类癌药耐受细胞的基因组范围的基因表达分析
Ulrike Olszewski,Robert Zeillinger,Klaus Geissler et al.
Ulrike Olszewski et al.
Purpose: Carcinoids are highly chemoresistant tumors associated with a dismal prognosis. This study involved a comparison of the genome-wide gene expression pattern of a chemoresistant and a chemosensitive pulmonary carci...
The role of maintenance pemetrexed in the treatment of non-small-cell lung cancer [0.03%]
维持性培美曲塞在非小细胞肺癌治疗中的作用
Saeed Rafii,Michael H Cullen
Saeed Rafii
Until recently, the weight of evidence has supported the discontinuation of chemotherapy in advanced non-small-cell lung cancer (NSCLC) after 4-6 cycles of induction therapy. This allows patients with limited life expectancy a "treatment ho...
Astragalus-containing Chinese herbal combinations for advanced non-small-cell lung cancer: a meta-analysis of 65 clinical trials enrolling 4751 patients [0.03%]
含黄芪的中药复方联合化疗治疗晚期非小细胞肺癌的Meta分析：基于65项临床研究4751例患者的证据评价
Jean Jacques Dugoua,Ping Wu,Dugald Seely et al.
Jean Jacques Dugoua et al.
Background: Non-small-cell lung cancer (NSCLC) is a leading cause of death. Interventions to reduce mortality in patients with NSCLC represent a patient-important field of research. Little is known about interventions use...
Circulating tumor cells (CTCs) in lung cancer: current status and future perspectives [0.03%]
肺癌循环肿瘤细胞（CTC）研究现状与未来展望
Fumihiro Tanaka,Kazue Yoneda,Seiki Hasegawa
Fumihiro Tanaka
Primary lung cancer is the leading cause of cancer-related deaths in most industrialized countries, and it is important to detect and control metastases distant from the lungs for improvement of a patient's prognosis. Circulating tumor cell...